JP2018520208A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520208A5
JP2018520208A5 JP2018513264A JP2018513264A JP2018520208A5 JP 2018520208 A5 JP2018520208 A5 JP 2018520208A5 JP 2018513264 A JP2018513264 A JP 2018513264A JP 2018513264 A JP2018513264 A JP 2018513264A JP 2018520208 A5 JP2018520208 A5 JP 2018520208A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dnase
composition according
administered
neurodegeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513264A
Other languages
English (en)
Japanese (ja)
Other versions
JP6745873B2 (ja
JP2018520208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/RU2016/000284 external-priority patent/WO2016190780A1/en
Publication of JP2018520208A publication Critical patent/JP2018520208A/ja
Publication of JP2018520208A5 publication Critical patent/JP2018520208A5/ja
Application granted granted Critical
Publication of JP6745873B2 publication Critical patent/JP6745873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513264A 2015-05-22 2016-05-11 神経変性における治療標的としての細胞外dna Active JP6745873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165255P 2015-05-22 2015-05-22
US62/165,255 2015-05-22
PCT/RU2016/000284 WO2016190780A1 (en) 2015-05-22 2016-05-11 Extracellular dna as a therapeutic target in neurodegeneration

Publications (3)

Publication Number Publication Date
JP2018520208A JP2018520208A (ja) 2018-07-26
JP2018520208A5 true JP2018520208A5 (enExample) 2019-09-19
JP6745873B2 JP6745873B2 (ja) 2020-08-26

Family

ID=57393467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513264A Active JP6745873B2 (ja) 2015-05-22 2016-05-11 神経変性における治療標的としての細胞外dna

Country Status (7)

Country Link
US (1) US11701410B2 (enExample)
EP (1) EP3297657B1 (enExample)
JP (1) JP6745873B2 (enExample)
CN (1) CN108289932A (enExample)
ES (1) ES2799515T3 (enExample)
RU (1) RU2726131C2 (enExample)
WO (1) WO2016190780A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン,ドミトリー 神経変性における治療標的としての細胞外dna
WO2018197547A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
US12274720B2 (en) 2017-05-24 2025-04-15 Viktor Veniaminovich Tets Methods for treating and preventing diseases
AU2018332326B2 (en) 2017-09-18 2025-04-03 Santersus Ag Method and device for purification of blood from circulating cell free DNA
JP2021510539A (ja) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドCLS Therapeutics Limited デオキシリボヌクレアーゼ(DNase)活性を有する酵素の肝臓発現による疾患の処置
EP3787638A4 (en) * 2018-04-30 2023-10-18 Tets, Viktor, Veniaminovich Tetz-proteins and prion-like proteins and associated methods
WO2020006357A1 (en) 2018-06-29 2020-01-02 Tets Viktor Veniaminovich Methods for diagnosis and treatment of type 1 diabetes
EP3813555A4 (en) * 2018-06-29 2022-03-30 Tets, Viktor, Veniaminovich COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA
CN110129245B (zh) * 2019-07-08 2020-12-04 南京工业大学 一株敲除胞外核酸酶ExeP的谷氨酸棒杆菌及其构建方法与应用
US20220241394A1 (en) * 2019-07-12 2022-08-04 Cls Therapeutics Limited TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY
EP4119149A1 (en) * 2021-07-15 2023-01-18 Foundation For Research And Technology Hellas Extracellular vesicles comprising a therapeutic cargo
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
DE68928934T2 (de) 1988-12-23 1999-08-05 Genentech, Inc., South San Francisco, Calif. Verfahren zur herstellung von menschlicher dnase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
AU7212694A (en) 1993-06-24 1995-01-17 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
JP2986215B2 (ja) 1994-03-04 1999-12-06 ジェネンテック インコーポレイテッド Dnアーゼ含有医薬製剤
US5830744A (en) 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
JP3173794B2 (ja) 1994-05-20 2001-06-04 久光製薬株式会社 タンパク質またはポリペプチド類とその製造法および中間化合物
JP4118334B2 (ja) 1996-02-05 2008-07-16 ジェネンテック・インコーポレーテッド ヒトdnアーゼ
US6156504A (en) 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6242426B1 (en) 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6455250B1 (en) 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
CN1243545C (zh) 1998-07-16 2006-03-01 研究发展基金会 切割dna的抗肿瘤剂
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
AU2156600A (en) 1998-11-25 2000-06-13 Cold Spring Harbor Laboratory Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000229881A (ja) 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
DE60035851D1 (de) 1999-08-17 2007-09-20 Tanuma Deoxyribonuklease, dafür kodierendes gen und verfahren
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
AU4430701A (en) 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
ES2527096T3 (es) * 2002-02-18 2015-01-20 Ockham Biotech Limited Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
DE60219809T2 (de) 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
AU2003298972A1 (en) 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
WO2005004904A1 (en) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
US8173618B2 (en) 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
EP1734991A4 (en) 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
EP3332808B1 (en) * 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
JP3989936B2 (ja) 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規dnアーゼ
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
BRPI0616012A2 (pt) 2005-07-18 2011-05-31 Protalix Ltd administração via mucosa ou intestino de macromoléculas biologicamente ativas
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
WO2008039989A2 (en) 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
AU2007311444B2 (en) 2006-10-18 2012-11-29 Periness Ltd. Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
KR20090087095A (ko) 2006-11-28 2009-08-14 드미트리 드미트리에비치 겐킨 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
EP2646055A4 (en) * 2010-12-02 2015-04-08 Immunomedics Inc COPPER-FREE IN VIVO CLICK CHEMISTRY FOR THE DISPOSAL OF THERAPY AND / OR DIAGNOSTIC PRODUCTS
US20130243794A1 (en) 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
BR112014020325A2 (pt) 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
NZ704039A (en) 2012-08-03 2018-04-27 Ferring Bv Cell-free dna as a therapeutic target for female infertility and diagnostic marker
JP6552511B2 (ja) 2013-10-11 2019-07-31 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
EP3119896B1 (en) 2014-03-21 2022-03-23 The Sydney Children's Hospitals Network (Randwick and Westmead) Stable gene transfer to proliferating cells
RU2727015C2 (ru) 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Векторы aav, нацеленные на центральную нервную систему
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン,ドミトリー 神経変性における治療標的としての細胞外dna
CN108348621A (zh) 2015-11-05 2018-07-31 竹治疗股份有限公司 用于基因治疗的经修饰的弗里德赖希共济失调基因及载体
WO2017147446A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Viral and oncoviral nuclease treatment

Similar Documents

Publication Publication Date Title
JP2018520208A5 (enExample)
RU2017145051A (ru) Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
HRP20191919T1 (hr) Donori nitroksila sa poboljšanim terapijskim indeksom
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2012505154A5 (enExample)
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
JP2018515101A5 (enExample)
EP4285991A3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
CR20220096A (es) Proteínas de fusión terapéuticas
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of heart disease
JP2009500045A5 (enExample)
EP3911329A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC LIVER DISEASES
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
JP2011504736A5 (enExample)
Cheon et al. Treatment of nail lichen Striatus with Intralesional steroid injection: A case report and literature review.
EP4154896A4 (en) Composition for prevention, alleviation, or treatment of respiratory disease
JP2015524808A5 (enExample)
EP2174666A4 (en) MEDICAL AGENT FOR THE PREVENTION OR TREATMENT OF ALZHEIMER DISEASE
JP2015517534A5 (enExample)
EP3632447A4 (en) Pharmaceutical composition for prevention or treatment of bone-related disease
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions
EP3690054A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
WO2012007658A3 (fr) Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives